Biomea Fusion

22 articles about Biomea Fusion

• Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

  9/28/2023

  Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced FDA and Health Canada clearance of the expansion portion of the ongoing COVALENT-111 Phase II study.

• Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

  8/31/2023

  Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the appointment of Juan Pablo Frías, M.D. as Chief Medical Officer (CMO).

• Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

  7/31/2023

  Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA) reported second quarter 2023 financial results and business highlights.

• BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population

  7/24/2023

  Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced preliminary topline data from its ongoing Phase I clinical trial, COVALENT-101, showcasing initial responses in relapsed/refractory AML patients with menin-dependent mutations.

• Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

  6/20/2023

  Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a potential treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association’s (ADA’s) 83rd Scientific Sessions, to be held June 23 – 26, 2023.

• Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

  5/2/2023

  Biomea Fusion, Inc. reported first quarter 2023 financial results and business highlights.

• Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

  5/1/2023

  Biomea Fusion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to begin a Phase I trial (COVALENT-103) of BMF-500.

• Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

  4/19/2023

  Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association (ADA) 83rd Scientific Sessions, to be held June 23 – 26, 2023 in San Diego, CA.

• Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

  4/13/2023

  Biomea Fusion, Inc. today announced the upcoming presentation of two preclinical abstracts at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida from April 14-19, 2023.

• Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  4/13/2023

  Biomea Fusion, Inc. today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of its common stock.

• Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock - March 30, 2023

  3/30/2023

  Biomea Fusion, Inc. announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $30.00 per share.

• Biomea Fusion Announces Proposed Public Offering of Common Stock - March 29, 2023

  3/29/2023

  Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.

• Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

  3/28/2023

  Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA) reported fourth quarter and full year 2022 financial results and business highlights.

• Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes

  3/28/2023

  Biomea Fusion, Inc. today announced initial positive topline data for the first two cohorts of patients with type 2 diabetes mellitus (T2DM) enrolled in the Phase II portion of its ongoing Phase I/II clinical study (COVALENT-111) of BMF-219, the company’s novel, investigational covalent menin inhibitor.

• Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET

  3/23/2023

  Biomea Fusion, Inc. today announced that it will host a conference call and webcast to discuss the initial clinical data from the first two cohorts of the Phase II portion of COVALENT-111 on Tuesday, March 28th at 8:30 am ET.

• Biomea Fusion To Participate In Upcoming Investor Events

  3/2/2023

  Biomea Fusion, Inc. today announced that Biomea’s management is scheduled to host investor meetings and participate in the following upcoming events.

• Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference

  11/11/2022

  Biomea Fusion, Inc. today announced that Biomea’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

• Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

  10/31/2022

  Biomea Fusion, Inc. today announced the dosing of the first patient with type 2 diabetes in the Phase II portion of COVALENT-111, a Phase I/II clinical trial underway in Canada.

• Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD)

  9/22/2022

  Biomea Fusion, Inc. presented “Oral long-acting menin inhibitor normalizes type 2 diabetes in two rat models” at the European Association for the Study of Diabetes Annual Meeting (EASD).

• Biomea Fusion to Participate in Jefferies Healthcare Conference

  6/2/2022

  Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat and meet with investors at the in-person Jefferies Healthcare Conference.